UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype

Cancer, 2011-11, Vol.117 (22), p.5058-5066

2011

Volltextzugriff (PDF)

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

Blood, 2009-06, Vol.113 (24), p.6069-6076

2009

Volltextzugriff (PDF)

Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models

Frontiers in immunology, 2023, Vol.14, p.1268979-1268979

2023

Volltextzugriff (PDF)

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents

Journal of cancer research and clinical oncology, 2016-02, Vol.142 (2), p.379-387

2016

Volltextzugriff (PDF)

Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma

Clinical cancer research, 2015-10, Vol.21 (19), p.4391-4397

2015

Volltextzugriff (PDF)

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

Clinical cancer research, 2008-03, Vol.14 (5), p.1561-1570

2008

Volltextzugriff (PDF)

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

Oncotarget, 2018-01, Vol.9 (3), p.4020-4033

2018

Volltextzugriff (PDF)

The future of CD20 monoclonal antibody therapy in B-cell malignancies

Leukemia & lymphoma, 2010-06, Vol.51 (6), p.983-994

2010

Volltextzugriff (PDF)

Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab

Cancer, 2013-10, Vol.119 (20), p.3662-3671

2013

Volltextzugriff (PDF)

Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model

Clinical cancer research, 2005-08, Vol.11 (16), p.5984-5992

2005

Volltextzugriff (PDF)

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

Blood, 2009-01, Vol.113 (5), p.1062-1070

2009

Volltextzugriff (PDF)

Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma

Clinical cancer research, 2012-02, Vol.18 (4), p.1039-1050

2012

Volltextzugriff (PDF)

Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression

Clinical cancer research, 2008-03, Vol.14 (5), p.1550-1560

2008

Volltextzugriff (PDF)

Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin’s lymphoma

Annals of hematology, 2015-04, Vol.94 (4), p.633-641

2015

Volltextzugriff (PDF)

Neutrophils Contribute to the Biological Antitumor Activity of Rituximab in a Non-Hodgkin’s Lymphoma Severe Combined Immunodeficiency Mouse Model

Clinical cancer research, 2003-12, Vol.9 (16), p.5866-5873

2003

Volltextzugriff (PDF)

CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells

Cancer immunology research, 2014-09, Vol.2 (9), p.878-889

2014

Volltextzugriff (PDF)

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Blood, 2014-02, Vol.123 (6), p.837-842

2014

Volltextzugriff (PDF)

Augmented Antitumor Activity against B-Cell Lymphoma by a Combination of Monoclonal Antibodies Targeting TRAIL-R1 and CD20

Clinical cancer research, 2007-08, Vol.13 (15), p.4556-4564

2007

Volltextzugriff (PDF)

Bendamustine for the treatment of indolent non-Hodgkin’s lymphoma and chronic lymphocytic leukemia

American journal of health-system pharmacy, 2010-05, Vol.67 (9), p.713-723

2010

Volltextzugriff (PDF)

A Quantitative Exploration of Surface Antigen Expression in Common B-Cell Malignancies Using Flow Cytometry

Immunological investigations, 2006, Vol.35 (1), p.93-114

2006

Volltextzugriff (PDF)

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody‐dependent cytotoxicity and improves overall survival against CD20+ rituximab‐sensitive/‐resistant Burkitt lymphoma (BL) and precursor B‐acute lymphoblastic leukaemia (pre‐B‐ALL): potential targeted therapy in patients with poor risk CD20+ BL and pre‐B‐ALL

British journal of haematology, 2015-12, Vol.171 (5), p.763-775

2015

Volltextzugriff (PDF)

Use of rituximab, the new FDA-approved antibody

Current opinion in oncology, 1998-11, Vol.10 (6), p.548-551

1998

Volltextzugriff (PDF)

Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma: Results From a Multicenter Study

Cancer, 2010, Vol.116 (1), p.106-114

2010

Volltextzugriff (PDF)

1 – 25 von 320

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(304)
Mit Volltextzugriff
(281)

Publikationsform

Artikel
(319)
Tagungsberichte
(1)

Sprache

Englisch
(320)
Japanisch
(25)

Erscheinungsjahr

n.n

Thema

Humans
(127)
Life Sciences & Biomedicine
(110)
Science & Technology
(110)
Oncology
(69)
Rituximab
(55)
Male
(51)
Female
(48)
Hematology
(48)
Middle Aged
(48)
Adult
(42)
Aged
(39)
Biological And Medical Sciences
(39)
Medical Sciences
(39)
Antineoplastic Agents - Therapeutic Use
(35)
Hematologic And Hematopoietic Diseases
(29)
Treatment Outcome
(28)
Antibodies, Monoclonal - Therapeutic Use
(27)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(26)
Prognosis
(26)
Animals
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents

Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

The future of CD20 monoclonal antibody therapy in B-cell malignancies

Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab

Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma

Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression

Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin’s lymphoma

Neutrophils Contribute to the Biological Antitumor Activity of Rituximab in a Non-Hodgkin’s Lymphoma Severe Combined Immunodeficiency Mouse Model

CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Augmented Antitumor Activity against B-Cell Lymphoma by a Combination of Monoclonal Antibodies Targeting TRAIL-R1 and CD20

Bendamustine for the treatment of indolent non-Hodgkin’s lymphoma and chronic lymphocytic leukemia

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Quantitative Exploration of Surface Antigen Expression in Common B-Cell Malignancies Using Flow Cytometry

Use of rituximab, the new FDA-approved antibody

Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma: Results From a Multicenter Study

Aktive Filter

Suchergebnisse filtern